{"entity":{"id":"nct04652076","kind":"trial","name":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","aka":["GYNET"],"tldr":"A phase 1/2 trial of Pembrolizumab and Carboplatin in endometrial cancer and cervical cancer, run by NETRIS Pharma, active and no longer recruiting.","summary":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab is a phase 1/2 interventional study registered as NCT04652076 by NETRIS Pharma, with 240 participants enrolled, started 2020-12-14 and due to reach its primary completion in 2025-10-30. Interventions recorded: NP137, Pembrolizumab, Paclitaxel and Carboplatin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04652076","url":"https://clinicaltrials.gov/study/NCT04652076"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","cervical","advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["pembrolizumab","carboplatin","np137"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04652076","phase":"1/2","setting":"A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination with Carboplatin Plus Paclitaxel And/or Pembrolizumab in Patients with Locally Advanced/metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/relapsing After At Least One Prior Systemic Chemotherapy.","sponsor":"NETRIS Pharma","participation":[{"nct":"NCT04652076","source":"https://clinicaltrials.gov/study/NCT04652076","fetchedAt":"2026-10-07T16:53:24.647Z","studySha256":"d0b51c4dc78a159c04ea7b0ff075506152f2ee9b2cb91b10deb95e660452284e","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2024-10-08","leadSponsor":"NETRIS Pharma","collaboratorCount":2,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"hasEligibility":true,"enrolment":240,"enrolmentType":"ESTIMATED","siteCount":15,"recruitingSiteCount":0,"countries":["France"]}],"started":"2020-12-14","startedType":"actual","enrolled":240,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04652076/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"np137","kind":"drug","name":"NP137","route":"/drugs/np137/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}